Trial SWITCH-II

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

SWITCH-II

Full title

Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma

NCT number

NCT01613846

Responsible organization

Urologie MRI Ismaninger Str.22 81675 München Germany

Indications

Classification	Code	Description
-		Other Urological tumors

Trial design

Phase

Status

Recruitment finished

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy

Zielgerichtet

Participants

	Function	Prename	Surname	Organization
	Responsible contact	Jürgen	Gschwend	Urologie MRI Ismaninger Str.22 81675 München Germany